BioCentury
ARTICLE | Emerging Company Profile

Anokion: Developing tolerance

Anokion using antigen-specific tolerance to develop less immunogenic drugs

June 9, 2014 7:00 AM UTC

Anokion S.A. is using its antigen-specific tolerance platform to develop less immunogenic versions of existing drugs. In the longer term, the company wants to use the technology to develop novel autoimmune therapeutics.

For existing protein drugs, Anokion's technology exploits a natural tolerance mechanism by conjugating the parent molecule to multiple copies of a peptide that binds glycophorin A (GYPA). GYPA is a surface protein unique to RBCs...